Seattle, WA, United States of America

Emma E Moore


 

Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 118(Granted Patents)


Company Filing History:


Years Active: 1996-2011

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents

Title: **Emma E Moore: A Leader in Pharmaceutical Innovations**

Introduction

Emma E Moore is a prominent inventor based in Seattle, WA, renowned for her significant contributions to the field of pharmaceuticals. With a remarkable portfolio that consists of 16 patents, she has established herself as a key figure in the development of innovative therapeutic solutions.

Latest Patents

Her latest invention, a pharmaceutical composition combining FGF18 and an IL-1 antagonist, has shown great promise in the treatment of IL-1 mediated diseases. FGF18 is recognized for its ability to stimulate the proliferation of chondrocytes, bone, and nervous tissue, facilitating the repair of damaged tissue. The invention emphasizes that when an IL-1 antagonist is administered alongside FGF18, the therapeutic effects on cartilage, bone, and nervous cell proliferation are significantly enhanced compared to using either treatment alone. This invention has the potential to transform approaches to treating various degenerative diseases.

Career Highlights

Emma has dedicated her career to advancing medical science, working diligently at Zymogenetics, Inc. Her innovative approaches and in-depth research have not only yielded multiple patents but have also contributed to the broader scientific community's understanding of complex biological mechanisms.

Collaborations

Throughout her career, Emma has collaborated with notable professionals like Charles R. Petrie and Patricia A. McKernan. These partnerships have allowed her to integrate diverse expertise into her projects, thereby enhancing the quality and impact of her inventions.

Conclusion

In conclusion, Emma E Moore is a trailblazer in the field of pharmaceutical innovations. Her latest patent work exemplifies her commitment to developing novel treatments that address substantial medical challenges. As she continues her work at Zymogenetics, Inc., we can anticipate further advancements that will likely improve the lives of many.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…